Prima Biomed Ltd. (PRR.AX)
-ASX 0.08 
0.00(1.28%) May 24, 2:10AM EDT
| Prev Close: | 0.08 |
|---|
| Open: | 0.08 |
|---|
| Bid: | 0.08 |
|---|
| Ask: | 0.08 |
|---|
| 1y Target Est: | 0.38 |
|---|
| Beta: | N/A |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 0.08 - 0.08 |
|---|
| 52wk Range: | 0.07 - 0.21 |
|---|
| Volume: | 601,101 |
|---|
| Avg Vol (3m): | 1,847,440 |
|---|
| Market Cap: | 82.09M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | N/A |
|---|
| Div & Yield: | N/A (N/A) |
|---|
Quotes delayed, except where indicated otherwise. Currency in AUD.
Headlines
- Prima BioMed to Present at the Second Annual Marcum LLP MicroCap ConferenceMarketwired(Mon, May 20)
- Prima BioMed Issues the Following Notice to Stockholders of the CompanyMarketwired(Thu, May 16)
- Russell J. Howard to Join Prima BioMed's Board of DirectorsMarketwired(Tue, May 7)
- Prima BioMed Updates Clinical Leadership TeamMarketwired(Tue, Apr 23)
- 19 April 2013 Prima BioMed Quaterly Results And Conference Call >>at Reuters(Fri, Apr 19)
- DGAP-News: Prima BioMed veröffentlicht Kapitalflussrechnung für das dritte Quartal und kündigt Telefonkonferenz anEquityStory(Fri, Apr 19)
- Prima Biomed Quarterly Results and Conference CallMarketwired(Fri, Apr 19)
- Prima BioMed Awarded Japanese Patent for CVac(TM)Marketwired(Wed, Apr 17)
- 11 April 2013 Share Purchase Plan Offer Documents >>at Reuters(Thu, Apr 11)
- DGAP-News: Prima BioMed Ltd.: Außerordentliche Hauptversammlung findet am 16. Mai 2013 in Sydney statt - Angebotsunterlagen des Aktienerwerbsplans auf Website verfügbarat Reuters(Thu, Apr 11)
- DGAP-News: Prima BioMed Ltd.: Aktualisierung des AktienerwerbsplansEquityStory(Tue, Apr 9)
- 09 April 2013 Share Purchase Plan Update >>at Reuters(Tue, Apr 9)
- DGAP-News: Prima BioMed Ltd.: BEABSICHTIGTER AKTIENERWERBSPLAN UND ANGEBOT ÜBER BÖRSENNOTIERTE OPTIONEN; EINBERUFUNG ZUR AUSSERORDENTLICHEN HAUPTVERSAMMLUNGat Reuters(Tue, Apr 2)
- 20 March 2013 3.8 million Euro grant to support CVac Development; Prima moving forward with pilot of CVac in additional cancer indications >>at Reuters(Wed, Mar 20)
- DGAP-News: Prima BioMed erhält 3,8 Mio. Euro Förderung für CVac(TM)-Entwicklung und forciert Pilot-Studien mit CVac bei weiteren KrebsindikationenEquityStory(Wed, Mar 20)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 54.78 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Jun-13)
: | -0.02 |
|---|
| Quarterly EPS Est
(0-00-31)
: | N/A |
|---|
| Mean Recommendation*: | 1.5 |
|---|
| PEG Ratio (5 yr expected): | -1.30 |
|---|
Business Summary
Prima BioMed Ltd, a biotechnology company, engages in the research and commercialization of licensed medical biotechnology products in Australia. It develops oncology therapies in the field of immunotherapy.
View More